Abstracts
Presenting an abstract at Summit4CI offers researchers, students, postdocs, research associates, technical staff, and industry professionals a platform to share their scientific findings with a broad and diverse audience, including international experts in immunotherapy, patient groups, and the cancer research community across Canada.
Abstract submission is now closed.
Abstract Guidelines
Scientific Abstracts
Scientific Abstracts are for an expert audience and must be 250 words or fewer. Abstract submission is open to all Summit4CI registrants. The adjudication committee seeks high quality and novel research relevant to the topic of the multidisciplinary fields of cancer immunotherapy and biotherapeutics.
Plain Language Abstracts (optional for HQP only)
Plain Language Abstracts are for a general audience, emphasizing clarity and accessibility.
HQP are invited to submit a plain language summary abstract. Plain Language presentations will be delivered alongside the poster sessions and will be judged by the BioCanRx Cancer Community Partnership (CCP). The top presenters will be awarded a prize given on behalf of the CCP.
Plain language abstracts must be 130 words or fewer. These summaries are targeted to our patient groups and other non-academic members attending the Summit4CI. To facilitate writing this document, we recommend you refer to the BC SUPPORT Unit's information page on this topic: https://www.bcahsn.ca/learning/plain-language-guide.
Late-Breaking Abstracts
The final late-breaking abstract deadline is January 30th, 2026 and are subject to availability of poster presentation spots. Late-breaking abstracts are not eligible for travel awards. See key dates below.
Presentation of Accepted Abstracts
The Summit4CI HQP Working Group and Adjudication Committee will select abstracts for presentation in the following formats during the conference:
- Up to 120 poster presentations
- Up to 12 speed poster presentations
- 9 oral talks for three concurrent sessions*
*New this year, we are excited to introduce three concurrent sessions for HQP oral presentation. Abstracts will be organized into three thematic tracks:
- Track 1: Discovery and Basic Research. This track invites abstracts in discovery and basic research encompassing topics related to: immunology, virology, or cell biology relevant to cancer immunotherapy, without the need for a direct therapeutic application.
- Track 2: Translational Research. This track invites abstracts presenting proof-of-concept data through to clinical research. Submissions may include early-stage or preclinical therapeutic approaches and platforms, or clinical trial correlatives.
- Track 3: CSEI, Manufacturing, Regulatory, Patient Engagement. This track invites abstracts on the clinical, social, legal or economic impact of novel immunotherapies, advancements in biomanufacturing, regulatory considerations, and patient or community engagement.
When submitting an abstract, presenters must select the track that best aligns with their research to ensure appropriate consideration and placement within the program. Please reach out to Julie Jonkhans ([email protected]) if you have any questions.
HQP Travel Awards
BioCanRx offers travel awards to highly ranked abstracts for the Summit4CI. These awards are available to highly qualified personnel (HQP), including undergraduate students, graduate students, postdoctoral fellows, research associates, and technical staff within an academic/clinical setting. Note that individuals eligible to receive CIHR funding are not eligible for HQP Travel Awards.
Travel award winners will be notified of their status in the travel award competition at least one week prior to the Summit’s early bird registration deadline.
Key Dates
Please note all deadlines are at 11:59 AM Pacific Time.
- Abstract submission deadline to be considered for a Travel Award (HQP only): November 7th, 2025
- Notifications of travel award success: Late December/early January, 2026
- Late-breaking abstract submission deadline: January 30th, 2026
- Notifications of abstract submission success: Early March 2026
Poster Guidelines (coming soon)
New BioCanRx Logo to include on posters and in slidedecks:
Submit your abstract